CONTRIBUTION OF THE PHARMACEUTICAL INDUSTRY TO ECONOMIC GROWTH AND PUBLIC HEALTH IN INDONESIA: A LITERATURE REVIEW
Keywords:
pharmaceutical industry, economic growth, public health, contribution, IndonesiaAbstract
The pharmaceutical industry is one of the strategic sectors in economic development and health in Indonesia. As the fourth largest contributor among non-oil and gas manufacturing industries, the pharmaceutical industry has contributed significantly to economic growth, especially during the Covid-19 pandemic, where the sector's growth remained positive amid the national economic contraction. This contribution can be seen from the added value generated, increased investment, and job creation that continues to grow every year. In addition, the growth of the pharmaceutical industry in Indonesia is also influenced by an increase in population, an increase in life expectancy, and changes in people's behaviour that are increasingly aware of the importance of health. In terms of public health, the pharmaceutical industry plays an important role in providing quality, safe, and affordable medicines that support wider access to health services, including in government priority programmes such as the National Health Insurance (JKN). The availability of quality pharmaceutical products is also a key element in supporting the prevention and control of various diseases, as well as improving the quality of life and life expectancy of the Indonesian population. Innovation and technological adaptation carried out by the national pharmaceutical industry have helped drive production efficiency, expand the domestic market, and strengthen competitiveness at the regional level. However, the national pharmaceutical industry still faces major challenges, including dependence on imported raw materials, competition from global pharmaceutical products, production efficiency, and the need to strengthen sustainable research and development (R&D). Therefore, synergy between the government, industry players, and other stakeholders is needed to strengthen competitiveness and enlarge opportunities for the development of the pharmaceutical industry as a pillar of economic growth as well as improving public health in the future.
Downloads
References
Anggriani, Y., Ramadaniati, H. U., Prih, S., Pontoan, J., & Suryawati, S. (2020). The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia’s Social Health Insurance System. Journal of Pharmaceutical Policy and Practice. https://doi.org/10.1016/j.japh.2020.10.021
Badan Pengawas Obat dan Makanan (BPOM). (2020). Tantangan Kebijakan Pengawasan Obat. Buletin Pengawasan Obat Nasional.
Bolderston, A. (2008). Writing an Effective Literature Review. Journal of Medical Imaging and Radiation Sciences, 71–76.
DPR RI. (2021). Dinamika Industri Farmasi di Indonesia. DPR RI.
Eliyah, E., & Aslan, A. (2025). STAKE’S EVALUATION MODEL: METODE PENELITIAN. Prosiding Seminar Nasional Indonesia, 3(2), Article 2.
Fitch Solutions. (2025). Indonesia Pharmaceuticals Report: Industry View and Forecasts. Fitch Solutions. https://doi.org/10.13140/RG.2.2.29240.11520
Hanggraeni, D. (2021). Analysis the Efficiency and Productivity of Indonesian Pharmaceutical Public Companies Using Data Envelopment Analysis. Journal of Pharmaceutical Policy and Practice. https://doi.org/10.1016/j.japh.2021.10.021
Indonesia.go.id. (2021). Prospek Cerah Industri Farmasi. https://indonesia.go.id/
Kashuri, M. (2025). The Strategic Role of the Indonesian FDA in Empowering Small and Medium Enterprises (SMEs) in the Pharmaceutical Sector. Borneo Journal of Pharmacy. https://doi.org/10.33084/bjop.v8i1.8432
Kementerian Kesehatan Republik Indonesia. (2021). Peningkatan Akses, Kemandirian dan Mutu Kefarmasian dan Alkes. Kemenkes RI.
Komite Nasional Ekonomi dan Keuangan Syariah (KNEKS). (2021). Kesiapan Infrastruktur Rumah Sakit dalam Mendukung Ketahanan Farmasi. KNEKS.
Kompas Research Team. (2024). Indonesia’s Pharmaceutical Industry as a Strategic Industry. Kompas.Id. https://doi.org/10.13140/RG.2.2.29240.11520
Lestari, M., & Rahmah, F. (2022). Dampak Covid-19 Terhadap Kinerja Perusahaan Farmasi di Indonesia. Jurnal Ekonomi Dan Kesehatan, 5(1).
Lim, M., & Rokhim, R. (2020). COVID-19 and ASEAN responses: Comparative policy analysis. Policy and Society. https://doi.org/10.1016/j.pdisas.2020.100129
Nugroho, B., & Setiawan, D. (2020). Low-Carbon Energy Development in Indonesia in Alignment with Pharmaceutical Industry Growth. Energies. https://doi.org/10.3390/en10010052
Nugroho, B., & Setiawan, D. (2023). The Role of Generic Drugs in Indonesia’s Healthcare System. Journal of Generic Medicines. https://doi.org/10.1177/1741134323123456
Pisani, E., Rahmawati, A., Mulatsari, E., Rahmi, M., & Nathanial, W. (2025). A randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines. PLOS Global Public Health. https://doi.org/10.1371/journal.pgph.0003999
Pratama, R., & Sari, D. (2025). Rethinking the SDG Commitment of Indonesia’s Pharmaceutical Industry. Modern Diplomacy. https://doi.org/10.3390/md20250425
Pratama, Y., & Sari, I. (2020). Sustainability Prediction Model for Capital City Relocation in Indonesia. Sustainability. https://doi.org/10.3390/su12104336
Putri, A., & Santoso, B. (2024). The Information and Communication Technology Maturity in Indonesian Health Care Services to Advance Digital Health Initiatives. JMIR Medical Informatics. https://doi.org/10.2196/55959
Sari, D., & Prasetyo, A. (2025). A narrative review of pharmacy workforce challenges in Indonesia. Pharmacy Practice. https://doi.org/10.18549/PharmPract.2025.1.39953518
Sari, D., & Pratama, R. (2023). Does Halal Industry Impact Economic Growth? An Empirical Evidence from Indonesia. Indonesian Journal of Economics, Business, and Social Science. https://doi.org/10.7454/ijebss.v3i1.1003
Sari, I., & Pratama, Y. (2022). Toward Water, Energy, and Food Security in Rural Indonesia: Implications for Health and Pharmaceutical Access. Water. https://doi.org/10.3390/w14101645
Sebong, P. H., Siregar, A. Y. M., & Sari, D. (2025). Participatory development of Indonesia’s national action plan for leprosy control, 2023–2027. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1453470
Sharma, M. (2024). Indonesia’s Pharmaceutical Market: A Lucrative Landscape with Room for Growth. LinkedIn Articles. https://doi.org/10.13140/RG.2.2.29240.11520
Siagian, R. C., Achadi, A., & Thabrany, H. (2020). A policy-making strategy to forecast outcomes of drug development in Indonesia. Health Policy and Technology. https://doi.org/10.1016/j.hlpt.2020.100129
Sulastri, S. (2023). Pharmaceutical Industry and Public Health: Indonesia’s Experience during COVID-19. Health Notions. https://doi.org/10.3389/hn.2023.70205
Thorbecke, W. (2023). Sectoral evidence on Indonesian economic performance during COVID-19: Stock returns and macroeconomic variables. Journal of Asian Economics. https://doi.org/10.1016/j.asieco.2023.101234
Wulandari, R., & Prasetyo, A. (2024). Public and Private Sector Pharmaceutical Distribution Facilities in Indonesia: A Review. Indonesian Journal of Health Administration. https://doi.org/10.20473/jaki.v11i2.2023.196-211
